Affitech A/S
Notification pursuant to Section 28(a) of the Danish Securities Trading Act
Affitech A/S 04.04.2012 17:33 Dissemination of a Adhoc News, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Release nr.8 2012 Copenhagen and Oslo 4th April 2012, 2012-04-04 17:33 CEST (GLOBE NEWSWIRE) -- Pursuant to Section 28a of the Danish Securities Trading Act, Affitech A/S shall make public information on transactions by managerial employees and their related parties involving Affitech shares and related instruments, as follows: Name Trans Nova Investments Limited ------------------------------------------------------------------------------ Reason for reporting Related party to Mr. Alexander Shuster who is chairman of the board of Affitech A/S ------------------------------------------------------------------------------ Issuer and ID code/ISIN Affitech A/S/DK0015966592 ------------------------------------------------------------------------------ Type of transaction Purchase of shares ------------------------------------------------------------------------------ Date of transaction 4 April 2012 ------------------------------------------------------------------------------ Relevant market NASDAQ OMX COPENHAGEN A/S ------------------------------------------------------------------------------ Number of traded securities 152,419,544 shares of nominal value DKK 0.50 each ------------------------------------------------------------------------------ Market value DKK 30,483,908.8 (152,419,544 shares each purchased at DKK 0.20) ------------------------------------------------------------------------------ Om Affitech Affitech A/S er en børsnoteret (NASDAQ OMX Copenhagen) biotekvirksomhed med hovedsæde i København, Danmark og forsknings- og udviklingsfaciliteter i Oslo, Norge. Affitech A/S udvikler 100 % humane antistoflægemidler baseret på række patenterede antistofteknologier. Affitech A/S' lægemiddelkandidater retter sig bl.a. mod kræft og betændelsestilstande. Affitech A/S' antistoflægemidler mod molekyler på celleoverfladen bliver udviklet på basis af Selskabets proprietære teknologiplatform CBAS(TM) (Cell Based Antibody Selection). Adskillige af de lægemiddelkandidater, Selskabet har rettighederne til, er udviklet ved hjælp af CBAS(TM) teknologien. Yderligere information fås på www.affitech.com Kontakt: Randi Krogsgaard, Director IR & Communications Tlf. +45 2320 100, e-mail ir@affitech.com News Source: NASDAQ OMX 04.04.2012 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Affitech A/S Denmark Phone: Fax: E-mail: Internet: ISIN: DK0015966592 WKN: End of Announcement DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden